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Background & objectives: In most of rural India, warfarin is the only oral anticoagulant available.
Among patients taking warfarin, there is a strong association between poor control of the international
normalized ratio (INR) and adverse events. This study was aimed to quantify INR control in a secondary
healthcare system in rural Chhattisgarh, India.
Methods: The INR data were retrospectively obtained from all patients taking warfarin during 2014-2016
at a secondary healthcare system in rural Chhattisgarh, India. Patients attending the clinic had their INR
checked at the hospital laboratory and their warfarin dose adjusted by a physician on the same day. The
time in therapeutic range (TTR) was calculated for patients who had at least two INR visits.
Results: The 249 patients had 2839 INR visits. Their median age was 46 yr, and the median body mass
index was 17.7 kg/m2. They lived a median distance of 78 km (2-3 h of travel) from the hospital. The
median INR was 1.7 for a target INR of 2.0-3.0 (n=221) and 2.1 for a target of 2.5-3.5 (n=28). The median
TTR was 13.0 per cent, and INR was subtherapeutic 66.0 per cent of the time. Distance from the hospital
was not correlated with TTR.
Interpretation & conclusions: INR values were subtherapeutic two-thirds of the time, and TTR values
were poor regardless of distance from the health centre. Future studies should be done to identify
interventions to improve INR control.
Key words Anticoagulation - international normalized ratio - stroke - TTR - warfarin

Atrial fibrillation (AF), both valvular and
non-valvular, carries an increased risk of stroke and
systemic embolism, which leads to major social and
economic burden. Without thromboprophylaxis, stroke
risk averages four per cent/year among patients with
non-valvular AF and 17-18 per cent/year among
patients with valvular AF1. Anticoagulation reduces
this risk by 64 per cent compared to placebo and halves
the risk compared with antiplatelet therapy2,3. The cost

of treating stroke can be ₹500,000 in the first year4,
a major burden given the 1.44-1.64 million strokes
diagnosed each year in India alone5.
In most of the rural India, warfarin is the only
oral anticoagulant available, but there are many
barriers to its optimal use. Warfarin requires frequent
monitoring and adjustment to maintain a therapeutic
range. Subtherapeutic values increase the risk of
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stroke and embolism in patients with AF6, whereas
supratherapeutic values increase the risk of intracranial
haemorrhage. Alternatives such as direct oral
anticoagulants (DOACs) are as effective as warfarin,
but these are prohibitively expensive for most rural
Indians and not approved for use in patients with severe
mitral stenosis or mechanical heart prostheses7.
Time in therapeutic range (TTR) is the standard
method of estimating the quality of anticoagulation
with warfarin8, and a goal of 70 per cent or more
improves outcomes9. Although some anticoagulation
clinics in high-income countries could meet this goal10,
US clinics average was 55 per cent11, and outside of
North America and Europe, TTR was often lower
including 46.5 per cent in South Africa and 50.1 in
Latin America12-14. Compared to patients with a TTR
of approximately >70 per cent, patients with a TTR
of approximately <50 per cent have double the risk of
ischaemic stroke, bleeding or death15.
Of the 45 countries that enrolled participants in
the ROCKET-AF trial, India had the lowest TTR of
any region, averaging 35.9 per cent14. These data were
collected from an urban centre, a setting with more
robust healthcare infrastructure than rural India. The
present study was aimed to characterize the quality
of anticoagulation with warfarin in a rural, secondary
healthcare system in Chhattisgarh, India, by quantifying
the TTR of warfarin patients and determining the
correlation of TTR with factors such as socio-economic
status, caste and distance from the hospital.
Methods
This was a retrospective observational study.
De-identified data were obtained from the Jan Swasthya
Sahyog (JSS) electronic medical record (EMR). All
patients who received warfarin between 2014 and
2016 at JSS or its subcentres were included. Patients
who lacked two or more INR values in any eight-week
period were excluded from the analysis.
Demographic, clinical and laboratory data were
abstracted from the EMR for all patients. Indication
for warfarin was abstracted manually. Distance to
the medical centre was ascertained from Google
Maps. All patients who had INR measured at least
twice during an eight-week period were included.
A Behnk Elektronik’s Thrombostat magnet-based
monitor (Norderstedt, Germany) was used to
measure INR values. Patients attending the clinic had
their INR checked in the hospital laboratory prior to

their appointments, and the results were uploaded
into the EMR by the time of their appointment 1-3 h
later. Warfarin was adjusted by the physician on the
same day after seeing and interviewing the patient
in the clinic.
Ethical approval for the study was obtained by
the Ethics Committee of the Emmanuel Hospital
Association, New Delhi and by the Washington
University School of Medicine’s IRB (#201612042).
Mean TTR was determined using the Rosendaal
linear interpolation method8. Analyses were done using
SAS version 9.4 (SAS Institute, Cary, NC, USA) and
SPSS version 25 (IBM Corp., Armonk, NY, USA).
Results
Demographic information of the patients is
shown in Table I. There were 249 patients receiving
warfarin, and 162 of them had more than one INR
visit (87 were excluded as they did not have at least
two INR readings in any eight-week period). There
was a median of nine INR visits per included patient
during the three-year study period. The median age
was 46 yr; 135 (54.2%) were female, and the median
body mass index was 17.7 kg/m2. Most patients were
form Chhattisgarh (n=175, 70.3%) and the remaining
were from Madhya Pradesh. Most patients were in the
scheduled tribe (ST, n=86, 34.5%) or other backward
class groups (OBC, n=86, 34.5%); 44 (7.7%) were
from scheduled caste group. The median distance from
the main JSS hospital was 78 km, which was slightly
lower (72 km) among patients with two or more INR
values greater than eight week apart. Indication for
warfarin is shown in Table II. Most patients (62.6%)
required warfarin for AF, and 10.0 per cent of patients
had mechanical valves. The median INR was 1.7 for
patients whose target INR was 2.0-3.0 and 2.1 for
those with a target of 2.5-3.5 (Table II). Most (n=221,
88.8%) patients had a target INR of 2.0-3.0 and 11.2
per cent (n=28) had a target of 2.5-3.5. All patients
with the higher target had mechanical mitral valve
replacements (MVRs). The median TTR of the entire
group of patients was 13.0 per cent (IQR 0-34.8).
The median time subtherapeutic was 77.5 per cent
(45-100), and the median time supratherapeutic
was 0.0 per cent (0-11.6). Distance showed no
correlation with TTR (Spearman’s rho <1%). TTR
was greatest among the scheduled caste [median 26.4
(IQR 10.7-44.5)] and lowest among scheduled tribes
(median 0.0, IQR 0-13.4, P<0.001). Median TTR
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Table I. Details of patients included in the study
Demographics

n (%)

Median

IQR

Age (yr)

249

46

36‑53

Height (cm)

222

155

250‑162

Weight (kg)

226

47.7

39.3‑54.8

BMI (kg/m2)

188

17.7

13.1‑20.8

Distance (km)

249

78

33‑149

Distance (km) (for patients with a TTR)

162

72

28‑143

BMI, body mass index; IQR, interquartile range; TTR, time in therapeutic range
Table II. Indications for warfarin, INR targets, and median
INRs in the study patients
Indication for warfarin

n (%)

AF without mechanical valve

156 (62.6)

Mechanical valve

25 (10.0)

LA or LV thrombus

12 (4.8)

DVT, PE or DVT prophylaxis

54 (21.6)

Unclear

2 (0.8)

Target INR
2.0‑3.0

221 (88.8)

2.5‑3.5

28 (11.2)

INR (target 2‑3), median (IQR)

1.7 (1.2‑2.4)

INR (target 2.5‑3.5), median (IQR)

2.1 (1.6‑2.8)

INRs per person, median (IQR)

9 (3‑19)

AF, atrial fibrillation; LA, left atrial; LV, left ventricular;
DVT, deep‑vein thrombosis; PE, pulmonary embolism; INR,
international normalized ratio
Table III. Time in therapeutic range
TTR

Median (%)

IQR

Median TTR

13.0

0‑34.8

Time below range

77.5

45.0‑100.0

Time above range

0.0

0‑11.6

General category

11.3

0‑34.7

OBC

20.0

0‑35.6

SC

26.4

10.7‑44.5

ST

0.0

0‑13.4

Other

2.8

2.8‑37.3

TTR by caste

TTR versus distance

Spearman’s ρ=0.009, P=0.906

SC, scheduled caste; ST, scheduled tribe; OBC, other
backward class

in OBCs was 20.4 (0-35.6) and 11.3 (0-34.7) in the
general category patients (Table III).

Discussion
Our study demonstrated that the quality of
anticoagulation in rural Chhattisgarh was poor. Overall,
TTR was very low with a median of 13.0 per cent. The
low TTR is a cause of concern because among patients
taking warfarin, mortality rises with lower TTR,
with the highest mortality seen in patients with <30
per cent TTR16. Several factors may have contributed
to the low TTR in this rural population such as lack of
infrastructure and poverty. Although we hypothesized
that distance also would contribute to low TTR,
there was no correlation between distance and TTR.
One explanation for this negative finding is that
distance may not capture the difficulty of reaching
the healthcare centre in terms of mode of transport
(private vehicle, public transport or on foot), lost
wages, childcare or cost of travel. However, a more
likely explanation may be that in an area where poor
public health infrastructure is ubiquitous, being
closer to an overwhelmed institution makes little
difference compared to being farther away.
Poverty also might have interfered with INR
control. TTR correlates with socio-economic level17,
and higher TTRs have been noted in anticoagulation
clinics in high-income countries10. TTR increased in
countries that implemented warfarin management
programmes18. However, a more sustainable, long-term
solution for rural India may lie in focusing on bolstering
the public health infrastructure rather than establishing
warfarin management programmes alone. Targeting
women may also improve impact, as women are known
to have poorer INR control than men19.
The TTR was low because patients spent
77.5 per cent of their time below their target INR.
The effectiveness of warfarin therapy declines
exponentially with subtherapeutic INR values, both in
patients with AF20 and among those with mechanical
valves21. Thus, these patients with subtherapeutic TTR
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received only a fraction of the potential benefit of their
warfarin therapy and would have high risks of stroke,
which could be reduced with better INR control.
The DOAC therapy, if available, would have been
an option for up to 84.2 per cent (210 of 249) of these
patients based on their indication for anticoagulation.
Warfarin is a fraction of the upfront cost of DOACs, but
has a greater monitoring burden and risk of intracranial
haemorrhage22. Although DOACs are not cost saving,
but these appear cost-effective among populations that
have low TTR values with warfarin23.
Patient self-testing may also be an option to
improve INR control. In a US Veteran’s Affairs study,
INR control was improved among patients who used
individual home point-of-care (POC) devices, even
when they had access to a managed anticoagulation
clinic24. Though individual POC devices would be very
expensive for the rural poor, a POC device shared in a
rural community (perhaps with the help of a community
health worker) could improve laboratory and clinical
outcomes.
Reducing the thrombotic tendency of mechanical
valves may also lead to improved TTR. The newly
designed On-X valve, for example, requires an INR
of only 1.5-2.025, which was common in this study.
If these valves were available for the rural poor who
required a MVR, their risk of stroke might decline.
The study had several limitations. First, only 162
of the 249 patients on warfarin had more than one visit,
allowing TTR to be calculated. It is unknown which
of the excluded patients established care elsewhere
and continued to take warfarin and who discontinued
warfarin. It is possible that because of this loss to
follow up, INR monitoring may actually be worse than
reported. Second, some patients might have run out of
warfarin for several days before they were seen in clinic,
which would have exaggerated the amount of time that
they were presumed to be subtherapeutic. Third, as we
did not have data on income or education level, we
used caste as a surrogate marker of socio-economic
status. Although several studies show that health
indicators vary by caste26, it would have been better
to have additional socio-economic variables. Finally,
we did not assess whether dietary factors contributed
to the subtherapeutic INR values in this population.
In a previous study, dietary vitamin K has had an
inconsistent effect on the therapeutic warfarin dose27.
In conclusion, the quality of anticoagulation in
rural Chhattisgarh was below standards, even among

patients with access to JSS health centres. Future
studies should focus on identifying potential
interventions in this population, such as access to
POC monitoring, genetic risk-based dosing, DOAC
therapy and the overall improvement of public health
infrastructure in this neglected area.
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